LivaNova

LivaNova is a global medical technology company that develops products and therapies for the head and heart. Its portfolio spans circulatory support, cardiopulmonary products, neuromodulation and sleep apnea solutions. Among its principal offerings is VNS Therapy, a vagus nerve stimulation treatment for drug-resistant epilepsy and difficult-to-treat depression, alongside devices for heart and lung support, advanced circulatory support and obstructive sleep apnea.

The company operates in more than 100 countries and employs nearly 4,000 people, a workforce drawn from over 70 nationalities. Its technical domains include medical device technology, neuromodulation, cardiopulmonary technology, circulatory support technology, sleep apnea therapy technology and electrical nerve stimulation therapy. The industries it serves comprise medical technology, healthcare, neurology, cardiology and sleep medicine.

LivaNova describes its work as patient-centric, stating that it treats its work "as if lives depend on it". The company is built on decades of experience and frames its purpose around outcomes such as seizure-free days, restful sleep, relief from depression and healthy hearts. For lawyers and compliance professionals, the company sits at the intersection of medical device regulation, pharmaceutical and therapeutic claims, and cross-border commercial operations across more than 100 jurisdictions.